CoChat

Real-world service costs for neovascular-AMD clinics in the United Kingdom: structured literature review and scenario analysis

Open access

The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: Current cost-effectiveness analyses (CEA) emphasize drug costs as the differentiator between NICE recommended anti-VEGF treatments but may neglect real-world non-drug costs of running nAMD services in the UK. To address this, this study identified real-world non-drug service cost items relevant to UK NHS nAMD clinics, including costs arising from operational strain (demand exceeding capacity). METHODS: Cost items were identified by a structured literature review of peer-reviewed and grey literature, and an expert panel of 10 UK-based ophthalmologists with relevance to real-world practice. These items underwent meta-synthesis and were then determined in a consensus exercise. RESULTS: Of 237 cost items identified, 217 (91.6%) met the consensus threshold of >0.51 and were included in the nAMD Service Non-Drug Cost Instrument (nAS). Sensitivity of cost items taken from UK Health Technology Assessment (HTA) using the nAS as the reference standard was low (HTAmin: 1.84%, 95% CI 0.50-4.65%; HTAmax: 70.51%, 95% CI 63.96-76.49%). False negative rates showed variable likelihood of misclassifying a service by cost burden depending on prevalence. Scenario analysis using cost magnitudes estimated annual per-patient clinic cost at £845 (within capacity) to £13,960 (under strain) compared to an HTAmin estimate of £210. Accounting for cost of strain under an assumed 50% increase in health resource utilization influenced cost-effectiveness in a hypothetical genericisation scenario. CONCLUSION: Findings suggested that HTA underestimates UK NHS nAMD clinic cost burden with cost of strain contributing substantial additional unmeasured expense with impact on CEA. Given potential undertreatment due to strain, durability is suggested as one of the relevant factors in CEA of nAMD anti-VEGF treatments due to robustness under limited capacity conditions affecting UK ophthalmology services.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/03007995.2024.2362278

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 70 references

Research works printed but not linked: 1

  1. British National Formulary (online). London: BMJ Group and Pharmaceutical Press. Updated September 2018. Available from: https://vnras.com/wp-content/uploads/pdf/BNF-76.pdf.

Cited by

See all 15

Metadata

Authors
Sivaprasad, S., Bailey, C., Downey, L., Gilbert, R., Gale, R., Kotagiri, A., Mahmood, S., Morgan-Warren, P., Napier, J., Narendran, N., Pearce, I., Rennie, C., Talks, J., Wojcik, R., & Jandhyala, R.
Affiliations
  • Moorfields Eye Hospital NHS Foundation Trust (GB)
  • University Hospitals Bristol and Weston NHS Foundation Trust (GB)
  • Hull University Teaching Hospitals NHS Trust (GB)
  • Department of Ophthalmology, Bayer PLC, Reading, UK
  • York Teaching Hospital NHS Foundation Trust (GB)
  • Sunderland Eye Infirmary (GB)
  • University of Manchester (GB)
  • Aston University (GB)
  • Royal Liverpool and Broadgreen University Hospital NHS Trust (GB)
  • University Hospital Southampton NHS Foundation Trust (GB)
  • Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
  • Senior Leadership Team, Medialis Ltd, UK
Corresponding author
Jandhyala, Ravi
Venue
Current Medical Research and Opinion
Published
2024-06-12
Volume
40
Issue
7
Pages
1221-1233
ISSN
  • 0300-7995 (ISSN-L)
  • 1473-4877
OpenAlex
W4399170971
Cited by
15
References
70
Citations by year
2026: 7 · 2025: 7 · 2024: 1
FWCI
5.30
Type
journal article
Language
en
Open access
Locations
  • Current Medical Research and Opinion (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
Keywords
neovascular age-related macular degeneration, anti-VEGF therapy, health resource utilization, cost-effectiveness, health technology assessment, undertreatment
MeSH terms
Cost-Benefit Analysis, United Kingdom, Humans, Health Care Costs, Angiogenesis Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Real-world service costs for neovascular-AMD clinics in the United Kingdom: structured literature review and scenario analysis. https://app.cochat.ai/papers/10.1080/03007995.2024.2362278
The paper
Sivaprasad, S., Bailey, C., Downey, L., Gilbert, R., Gale, R., Kotagiri, A., Mahmood, S., Morgan-Warren, P., Napier, J., Narendran, N., Pearce, I., Rennie, C., Talks, J., Wojcik, R., & Jandhyala, R. (2024). Real-world service costs for neovascular-AMD clinics in the United Kingdom: structured literature review and scenario analysis. Current Medical Research and Opinion. https://doi.org/10.1080/03007995.2024.2362278

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.